Overview

Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

Status:
Unknown status

Trial end date:
2019-11-01

Target enrollment:

Participant gender:

Summary

Agents of sanchi have been widely used as a complementary medicine for stroke in China. Sanchitongshu is a new Chinese patent medicine extracted from sanchi which has stronger anti-platelet activity than other agents of sanchi. The investigators's aim was to investigate the synergistic action of aspirin combined with sanchitongshu capsule in the treatment of patients with minor ischemic stroke and transient ischemic attack.

Phase:

N/A

Details

Lead Sponsor:

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Aspirin
Clopidogrel
Ticlopidine